| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.096 | 0.05 |